A review of the efficacy and safety of oral antidiabetic drugs

Expert Opinion on Drug Safety

Volumn 12, Issue 2, 2013, Pages 153-175

  Stein, Stephanie Aleskow ^a   Lamos, Elizabeth Mary ^a   Davis, Stephen N ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

glucosidase inhibitor; Bile acid sequestrant; Bromocriptine; DPP 4 inhibitor; Meglitinide; Metformin; Sulfonylurea; Thiazolidinedione; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; ATAZANAVIR; BILE ACID SEQUESTRANT; BROMOCRIPTINE MESILATE; CLARITHROMYCIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETOCONAZOLE; LINAGLIPTIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TRIMETHOPRIM; UNINDEXED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; ARTHRALGIA; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONSTIPATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBROSIS; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HALLUCINATION; HEADACHE; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; HYPOTENSION; INSULIN RELEASE; LIVER DYSFUNCTION; LIVER TOXICITY; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PANCREAS ISLET BETA CELL; PANCREATITIS; PERIPHERAL EDEMA; POLYPHARMACY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH EMPTYING; URINARY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; TREATMENT OUTCOME;

EID: 84874184400     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.752813     Document Type: Review

References (163)

1. Inzucchi S E, Bergenstal R M, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: B patient-centered approach. position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
2. Bennett W L, Maruthur N M, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: Bn update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13
3. Roumie C L, Hung A M, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: B cohort study. Ann Intern Med 2012;157:601-10
4. Goldberg R B, Kendall D M, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54 (Pubitemid 40923063)
5. Deeg M A, Buse J B, Goldberg R B, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30:2458-64 (Pubitemid 47547772)
6. Dormandy J A, Charbonnel B, Eckland D J, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): B randomised controlled trial. Lancet 2005;366:1279-89 (Pubitemid 41416583)
7. Tontonoz P, Nagy L, Alvarez J G, et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-52 (Pubitemid 28180857)
8. Febbraio M, Podrez E A, Smith J D, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000;105:1049-56 (Pubitemid 30217689)
9. Nissen S E, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71 (Pubitemid 46919772)
10. Nissen S E, Wolski K. Rosiglitazone revisited: Bn updated meta-Analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201
11. Kahn S E, Zinman B, Lachin J M, et al. Rosiglitazone-Associated fractures in type 2 diabetes: Bn analysis from A diabetes outcome progression trial (ADOPT). Diabetes Care 2008;31:845-51
12. Kahn S E, Haffner S M, Heise M A, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43 (Pubitemid 44903747)
13. Mcintyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;2:20-1
14. Matsuyama T, Komatsu R, Namba M, et al. Glucagon-like peptide-1 (7-36 amide): B potent glucagonostatic and insulinotropic hormone. Diabetes Res Clin Pract 1988;5:281-4
15. Wettergren A, Schjoldager B, Mortensen P E, et al. Truncated GLP-1 (proglucagon 78-107-Amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73 (Pubitemid 23121274)
16. Tourrel C, Bailbe D, Meile M J, et al. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-Treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562-70 (Pubitemid 33639596)
17. Perfetti R, Zhou J, Doyle M E, et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-5 (Pubitemid 32055138)
18. Holz GG I V, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993;361:362-5 (Pubitemid 23041630)
19. Herman G A, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase I V, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88 (Pubitemid 41773643)
20. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
21. Golightly L K, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51:501-14
22. Deacon C F, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010;19:133-40
23. Herman G A, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase I V, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88 (Pubitemid 41773643)
24. Dhillon S, Weber J. Saxagliptin. Drugs 2009;69:2103-14
25. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet 2012;51:411-27
26. He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 2012;51:147-62
27. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: B randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008;30:499-512 (Pubitemid 351483925)
28. Aschner P, Kipnes M S, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7 (Pubitemid 44912190)
29. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
30. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-11
31. Del Prato S, Barnett A H, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: B randomized controlled trial. Diabetes Obes Metab 2011;13:258-67
32. Pi-Sunyer F X, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8 (Pubitemid 46240373)
33. DeFronzo R A, Fleck P R, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: B randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-17
34. Aschner P, Katzeff H L, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252-61
35. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007;24:955-61 (Pubitemid 47301637)
36. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-Analysis. BMJ 2012;344:e1369
37. Nauck M A, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: B randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205 (Pubitemid 46206563)
38. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: B randomised, double-blind, non-inferiority trial. Lancet 2012;380:475-83
39. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: B randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-8
40. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: B 2-year study. Int J Clin Pract 2010;64:562-76
41. Goldstein B J, Feinglos MN, Lunceford J K, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87 (Pubitemid 47219404)
42. DeFronzo R A, Hissa M N, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-55
43. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45 (Pubitemid 47261855)
44. Rosenstock J, Brazg R, Andryuk P J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: B 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68 (Pubitemid 44841980)
45. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167-77
46. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55 (Pubitemid 46701545)
47. Scheen A J, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-9
48. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008;4:753-68
49. Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010;24:79-83
50. De Meester I, Korom S, Van Damme J, et al. CD26, let it cut or cut it down. Immunol Today 1999;20:367-75 (Pubitemid 29356431)
51. Lankas G R, Leiting B, Roy R S, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94 (Pubitemid 41401097)
52. Engel S S, Williams-Herman DE, Golm G T, et al. Sitagliptin: Review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-90
53. Profit L, Chrisp P, Nadin C. Vildagliptin: The evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid 2008;3:13-30
54. Frederich R, Alexander J H, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
55. Johansen O E, Neubacher D, von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: B pre-specified, prospective, and adjudicated meta-Analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3
56. Schweizer A, Dejager S, Foley J E, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: Meta-Analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab 2010;12:485-94
57. Sitagliptin cardiovascular outcome study (0431-082 AMI) (TECOS) [internet] [Internet]. 2012.Available from: Http://clinicaltrials. gov/ct2/show/NCT00790205? term=TECOS&rank=1
58. Cardiovascular outcomes study of alogliptin in subjects with type 2 diabetes and acute coronary syndrome (EXAMINE) [Internet]. 2012.Available from: Http://clinicaltrials. gov/ct2/show/NCT00968708? term=EXAMINE&rank=1
59. Cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes (CAROLINA) [internet] [Internet]. 2012.Available from: Http://clinicaltrials. gov/show/NCT01243424
60. Scirica B M, Bhatt D L, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-Thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162:818-25.e6
61. Barzilai N, Guo H, Mahoney E M, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: B randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-58
62. Patel C G, Li L, Girgis S, et al. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: Simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol 2011;3:13-25
63. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): Focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88
64. Chan J C, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55 (Pubitemid 351850898)
65. Nowicki M, Rychlik I, Haller H, et al. Long-Term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: B randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011;65:1230-9
66. Migoya E M, Stevens C H, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009;16:e165-70
67. Boulton D W, Li L, Frevert E U, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-65
68. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet 2012;51:411-27
69. Polonsky K S, Given B D, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:1231-9
70. Gromada J, Dissing S, Kofod H, et al. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995;38:1025-32
71. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Insulinotropic action of meglitinide analogs: Concentration-response relationship and nutrient dependency. Diabetes Res 1994;27:81-7
72. Hu S, Wang S, Fanelli B, et al. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: B comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 2000;293:444-52 (Pubitemid 30244093)
73. Owens D R, Luzio S D, Ismail I, et al. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000;23:518-23 (Pubitemid 30185797)
74. Jovanovic L, Dailey G III, Huang WC, et al. Repaglinide in type 2 diabetes: B 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000;40:49-57
75. Moses R G, Gomis R, Frandsen KB, et al. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001;24:11-15 (Pubitemid 32104212)
76. Derosa G, Mugellini A, Ciccarelli L, et al. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract 2003;60:161-9 (Pubitemid 36561617)
77. Madsbad S, Kilhovd B, Lager I, et al. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: B 1-year multicentre study. Diabet Med 2001;18:395-401 (Pubitemid 32679389)
78. Marbury T, Huang W C, Strange P, et al. Repaglinide versus glyburide: B one-year comparison trial. Diabetes Res Clin Pract 1999;43:155-66 (Pubitemid 29202125)
79. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-24 (Pubitemid 29028307)
80. Jovanovic L, Hassman D R, Gooch B, et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004;63:127-34 (Pubitemid 38096358)
81. Rosenstock J, Hassman DR, Madder R D, et al. Repaglinide versus nateglinide monotherapy: B randomized, multicenter study. Diabetes Care 2004;27:1265-70 (Pubitemid 38679968)
82. NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-76
83. Schwarz S L, Gerich J E, Marcellari A, et al. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. Diabetes Obes Metab 2008;10:652-60 (Pubitemid 352044295)
84. Del Prato S, Heine R J, Keilson L, et al. Treatment of patients over 64 years of age with type 2 diabetes: Experience from nateglinide pooled database retrospective analysis. Diabetes Care 2003;26:2075-80 (Pubitemid 41184255)
85. Hatorp V, Hansen K T, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003;43:649-60 (Pubitemid 36613124)
86. Niemi M, Backman J T, Neuvonen M, et al. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2000 68:495-500
87. Niemi M, Backman J T, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: Potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003;46:347-51 (Pubitemid 36547589)
88. Niemi M, Kajosaari L I, Neuvonen M, et al. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004;57:441-7 (Pubitemid 38519649)
89. Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46:93-108 (Pubitemid 46193056)
90. Hasslacher C; Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886-91 (Pubitemid 36929360)
91. Devineni D, Walter Y H, Smith HT, et al. Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol 2003;43:163-70 (Pubitemid 36125943)
92. Choudhury S, Hirschberg Y, Filipek R, et al. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Pharmacol 2000;40:634-40
93. Lopez-Garcia F, Borras J, Verdu C, et al. Cholestatic hepatitis associated with repaglinide. Diabetes Care 2005;28:752-3 (Pubitemid 40315345)
94. Jaiswal S, Mehta R, Musuku M, et al. Repaglinide induced acute hepototoxicity. JNMA J Nepal Med Assoc 2009;48:162-4
95. Nan D N, Hernandez JL, Fernandez-Ayala M, et al. Acute hepatotoxicity caused by repaglinide. Ann Intern Med 2004;141:823
96. Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest 1994;24(SUPPL3):3-10
97. Lee A, Patrick P, Wishart J, et al. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002;4:329-35 (Pubitemid 34947095)
98. Takei I, Miyamoto K, Funae O, et al. Secretion of GIP in responders to acarbose in obese type 2(NIDDM) patients. J Diabetes Complications 2001;15:245-9 (Pubitemid 32754817)
99. Enc F Y, Imeryuz N, Akin L, et al. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol 2001;281:G752-63
100. Groop P H, Groop L, Totterman KJ, et al. Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects. Acta Endocrinol (Copenh) 1986;112:361-6 (Pubitemid 16061987)
101. Derosa G, Maffioli P, Ferrari I, et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol 2011;651:240-50
102. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen study. Diabetes Care 1994;17:561-6 (Pubitemid 24161978)
103. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-Treated NIDDM patients: The Essen-II study. Am J Med 1997;103:483-90 (Pubitemid 28018650)
104. Halimi S, Le Berre M A, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: B double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000;50:49-56 (Pubitemid 30629019)
105. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-Treated patients with type 2 diabetes. Diabetes Care 1998;21:2050-5 (Pubitemid 28549150)
106. Phillips P, Karrasch J, Scott R, et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003;26:269-73 (Pubitemid 36929042)
107. Costa B, Pinol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: B randomised-multicentric trial in primary health-care. diabetes and acarbose research group. Diabetes Res Clin Pract 1997;38:33-40 (Pubitemid 27428466)
108. Chiasson J L, Josse R G, Hunt J A, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994;121:928-35
109. Holman R R, Cull C A, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. prospective diabetes study 44). Diabetes Care 1999;22:960-4 (Pubitemid 29241052)
110. van de Laar F A, Lucassen PL, Akkermans R P, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: Results from a cochrane systematic review and meta-Analysis. Diabetes Care 2005;28:154-63 (Pubitemid 40095800)
111. Van de Laar F A, Lucassen PL, Akkermans R P, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005(2):CD003639
112. Coniff R F, Shapiro J A, Seaton TB. Long-Term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994;154:2442-8 (Pubitemid 24348155)
113. Chiasson J L, Josse R G, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359:2072-7 (Pubitemid 34680970)
114. Chiasson J L, Josse R G, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003;290:486-94 (Pubitemid 37430502)
115. Josse R G, Chiasson J L, Ryan E A, et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003;59:37-42 (Pubitemid 35461908)
116. Meneilly G S, Ryan E A, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000;23:1162-7 (Pubitemid 30616806)
117. Miura T, Ueno K, Tanaka K, et al. Impairment of absorption of digoxin by acarbose. J Clin Pharmacol 1998;38:654-7 (Pubitemid 28354905)
118. Precose (package insert) [Internet]. Wayne, New Jersey: Bayer Health Care Pharmaceuticals Inc.; 2008.Available from: Http://www. accessdata.fda.gov/ drugsatfda-docs/label/2008/020482s023lbl.pdf
119. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-Term, double-blind, crossover trial. Ann Intern Med 1994;121:416-22
120. Staels B. A review of bile acid sequestrants: Potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus. Postgrad Med 2009;121:25-30
121. Shang Q, Saumoy M, Holst J J, et al. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol 2010;298:G419-24
122. Bays H E, Goldberg R B, Truitt K E, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: Glucose and lipid effects. Arch Intern Med 2008;168:1975-83
123. Fonseca V A, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-84
124. Goldberg R B, Fonseca V A, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-40
125. Goldfine A B, Fonseca V A, Jones MR, et al. Long-Term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res 2010;42:23-30
126. Rigby S P, Handelsman Y, Lai Y L, et al. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract 2010;16:53-63
127. Ovalle F, Philis-Tsimikas A, Truitt K, Colesevelam HCL. improves glycemic control, independent of age in patients with type 2 diabetes uncontrolled on metformin, sulfonylurea, or insulin-based therapy. Diabetes 2007;56:A536
128. Donovan J M, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000;14:681-90 (Pubitemid 32217192)
129. Brown K S, Armstrong I C, Wang A, et al. Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. J Clin Pharmacol 2010;50:554-65
130. Weitzman S P, Ginsburg KC, Carlson HE. Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine. Thyroid 2009;19:77-9
131. Wechol (package insert) [Internet]. New York, New York: Sankyo Pharma Inc. 2008.Available from: Http://www. accessdata.fda.gov/drugsatfda-docs/label/ 2006/021176s014lbl.pdf
132. Trivedi C D, Pitchumoni CS. Drug-induced pancreatitis: Bn update. J Clin Gastroenterol 2005;39:709-16
133. Merten D F, Grossman H. Intestinal obstruction associated with cholestyramine therapy. AJR Am J Roentgenol 1980;134:827-8 (Pubitemid 10095916)
134. Lloyd-Still JD. Cholestyramine therapy and intestinal obstruction in infants. Pediatrics 1977;59:626-7
135. Luo S, Meier A H, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology 1998;68:1-10 (Pubitemid 28310603)
136. Cincotta A H, Schiller B C, Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism 1991;40:639-44
137. Cycloset (package insert) [Internet]. Cincinnati, Ohio: Pantheon Inc. 2009.Available from: Http://www. accessdata.fda.gov/drugsatfda-docs/label/2009/ 020866lbl.pdf
138. Cincotta A H, Meier A H, Cincotta M Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: B new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999;8:1683-707 (Pubitemid 29460532)
139. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: B novel approach to the treatment of type 2 diabetes. Diabetes Care 2000;23:1154-61 (Pubitemid 30616805)
140. Aminorroaya A, Janghorbani M, Ramezani M, et al. Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res 2004;62:55-9 (Pubitemid 39274252)
141. Ramteke K B, Ramanand SJ, Ramanand J B, et al. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Indian J Endocrinol Metab 2011;15:S33-9
142. Gaziano J M, Cincotta AH, O'Connor C M, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33:1503-8
143. Scranton R E, Gaziano J M, Rutty D, et al. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either cycloset or placebo. BMC Endocr Disord 2007;7:3
144. Forez H, Scranton R, Farwell W R, et al. Randomized clinical trial assessing the efficacy and safety of bromocriptine-QR when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. J Diabetes Metabolism 2011;2:142
145. Bloomgarden Z T, Dodis R, Viscoli CM, et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: B meta-regression analysis. Diabetes Care 2006;29:2137-9 (Pubitemid 44871202)
146. Neutel C I, Campbell N R, Morrison HI. Trends in diabetes treatment in Canadians, 1994-2004. Chronic Dis Can 2010;30:107-11
147. Desai N R, Shrank W H, Fischer MA, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: Quality and cost implications. Am J Med 2012;125:302.e1,302.e7
148. Kanai Y, Lee W S, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93:397-404
149. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-18
150. Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010;1:57-92
151. Banerjee S K, Wang D W, Alzamora R, et al. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J Mol Cell Cardiol 2010;49:683-92
152. Ferrannini E, Ramos S J, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: B randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
153. Nauck M A, Del Prato S, Meier J J, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: B randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22
154. Henry R R, Murray A V, Marmolejo MH, et al. Dapagliflozin, metformin X R, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66:446-56
155. Strojek K, Yoon K H, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: B randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928-38
156. Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-8
157. Wilding J P, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Bpplicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-62
158. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-Activated receptors. Lancet 1999;354:141-8 (Pubitemid 29313157)
159. Long G G, Reynolds VL, Lopez-Martinez A, et al. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: Lack of evidence for urolithiasis as an inciting event. Toxicol Pathol 2008;36:218-31 (Pubitemid 351545780)
160. Wilding J P, Gause-Nilsson I, Persson A, et al. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diab Vasc Dis Res 2007;4:194-203 (Pubitemid 47529209)
161. Rubin. C J, Ledeine J M, Fiedorek FT, Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: Bn active-control trial with glimepiride. Diab Vasc Dis Res 2008;5:168-76
162. Sanwald-Ducray P, Liogier D'ardhuy X, Jamois C, et al. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: Results from a randomized, placebo-controlled clinical study. Clin Pharmacol Ther 2010;88:197-203
163. Henry R R, Lincoff A M, Mudaliar S, et al. Effect of the dual peroxisome proliferator-Activated receptor-Alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): B phase II, randomised, dose-ranging study. Lancet 2009;374:126-35